CD274 and neoplasm: For instance, the inclusion criteria for the KEYNOTE 010, KEYNOTE 024, and CHECKMATE 026 trials involved PD-L1 tumor-expression positivity, while by contrast, the CHECKMATE 017 and CHECKMATE 057 trials enrolled patients with NSCLC without considering their PD-L1 status [64].